Physician profile
Leslie Jump
NPI 1063718237
$4,011.36
in general payments reported to CMS, 2019-2025
26 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $1,082 · 2024: $1,293 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $76.24 · Consulting Fee: $16.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.05 |
| Education | $76.24 |
| Consulting Fee | $16.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $850.69 | 2021-2025 | Airsupra, Tezspire, Bevespi Aerosphere |
| Genzyme Corporation | $468.92 | 2022-2025 | |
| Optinose US, INC. | $398.74 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $338.78 | 2021-2024 | Dupixent |
| Genentech USA, INC. | $299.37 | 2022-2025 | Xolair |
| Glaxosmithkline, LLC. | $279.99 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $240.00 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $164.30 | 2025 | Neffy |
| Abbvie INC. | $147.06 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $131.79 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $90.12 | 2021-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $82.71 | 2021-2025 | |
| Octapharma USA, INC. | $76.66 | 2021-2025 | Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $75.63 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $65.72 | 2024 | Hizentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $53.62 | 2025 | Dawnzera, Donidalorsen |
| Alk-Abello, INC | $50.04 | 2021-2022 | |
| Pharming Healthcare, INC. | $48.16 | 2025 | Ruconest |
| Pfizer INC. | $41.61 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $21.20 | 2021 | |
| Lilly USA, LLC | $20.36 | 2025 | Ebglyss |
| Amgen INC. | $16.71 | 2025 | Tezspire |
| Adma Biomanufacturing LLC | $16.37 | 2025 | |
| Aimmune Therapeutics, INC. | $15.47 | 2022 | |
| Kaleo, INC. | $14.58 | 2022 | |
| Organon LLC | $2.76 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Jump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.